Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $121,183.87 in Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Carmen Jeffrey Del sold 7,541 shares of the company’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $16.07, for a total transaction of $121,183.87. Following the completion of the sale, the insider now owns 18,427 shares of the company’s stock, valued at approximately $296,121.89. The transaction was disclosed in a filing with the SEC, which is available through this link.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX traded down $0.07 during trading on Tuesday, hitting $15.56. 782,963 shares of the company’s stock traded hands, compared to its average volume of 1,343,294. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of 28.81, a PEG ratio of 1.33 and a beta of 0.73. Catalyst Pharmaceuticals, Inc. has a 12-month low of $11.48 and a 12-month high of $17.50. The business has a 50 day moving average of $15.65 and a 200-day moving average of $15.26.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.31 EPS for the quarter, meeting the consensus estimate of $0.31. The business had revenue of $98.51 million for the quarter, compared to the consensus estimate of $97.24 million. Catalyst Pharmaceuticals had a net margin of 15.83% and a return on equity of 25.08%. On average, analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.78 EPS for the current year.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of CPRX. Janus Henderson Group PLC lifted its holdings in shares of Catalyst Pharmaceuticals by 139.5% in the first quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock worth $43,445,000 after buying an additional 1,587,794 shares in the last quarter. Boston Partners lifted its holdings in shares of Catalyst Pharmaceuticals by 965.2% in the fourth quarter. Boston Partners now owns 1,541,660 shares of the biopharmaceutical company’s stock worth $25,610,000 after buying an additional 1,396,930 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 12.1% in the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after buying an additional 860,244 shares in the last quarter. Mesirow Institutional Investment Management Inc. purchased a new stake in shares of Catalyst Pharmaceuticals in the first quarter worth about $11,463,000. Finally, Kennedy Capital Management LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 101.1% in the first quarter. Kennedy Capital Management LLC now owns 1,061,704 shares of the biopharmaceutical company’s stock worth $16,924,000 after buying an additional 533,802 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on CPRX. Cantor Fitzgerald restated an “overweight” rating and set a $34.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, March 22nd. HC Wainwright restated a “buy” rating and set a $26.00 price target on shares of Catalyst Pharmaceuticals in a research report on Monday, June 3rd. Oppenheimer restated an “outperform” rating and set a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, June 6th. Citigroup began coverage on shares of Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They set a “buy” rating and a $27.00 price target for the company. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $26.71.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.